Oncology & Cancer

The story of GARP: a potential target for cancer immunotherapy

Colorectal cancer is the third leading cause of cancer-related deaths in both men and women. Despite significant advances in therapies for this particular cancer, the five-year survival rate is 12 percent, according to the ...

Oncology & Cancer

Scientists design protein that prods cancer-fighting T-cells

Scientists at UW Medicine's Institute for Protein Design (IPD) in Seattle have created a new protein that mimics the action of a key immune regulatory protein, interleukin 2 (IL-2).  IL-2 is a potent anticancer drug and ...

Oncology & Cancer

Researchers suggest new treatment for rare inherited cancers

Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

Oncology & Cancer

New cancer immunotherapy drugs rapidly reach patients after approval

The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies ...

page 6 from 18